# US 2005/0032673 A1 · Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032673 A1
- Document ID: US20050032673A1
- Status: Published application
- Kind: A1
- Application number: 10/726,198
- Filed: 2003-12-02
- Published: 2005-02-10
- Earliest claimed: 2002-06-10
- Inventors: Constance John; Gary Jarvis; Hakon Leffler
- Web page: https://patentgrep.com/patent/US20050032673A1

## CPC

- C07K 14/4726: {Lectins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

There is provided a composition for anti-cancer or anti-inflammatory treatment having an effective amount of N-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding N-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating disease by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3, its homologues, antibody to galectin-3 carbohydrate binding sites, or a nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Further, there is provided a disease treatment having an effective amount of N-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding N-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier.

## Claims

### Claim 1

A composition comprising an effective amount of N-terminally truncated galectin-3 and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein said N-terminally truncated galectin-3 has a sequence according to SEQ ID NO: 1 and analogues thereof.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein said N-terminally truncated galectin-3 is present in an amount sufficient to reduce tumor size.

### Claim 4 (depends on 1)

The composition according to claim 1 for use in for treating cancer.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein said N-terminally truncated galectin-3 has a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.

### Claim 6 (depends on 5)

The composition according to claim 5, wherein said analogues and homologues include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein said composition in formulated for slow release.

### Claim 8 (depends on 1)

A method of treating a tumor in a patient by administering to a patient in need of treatment an effective amount of N-terminally truncated galectin-3 according to claim 1, in a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said administering step includes administering N-terminally truncated galectin-3 having a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said administering step includes administering analogues and homologues that include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.

### Claim 11 (depends on 1)

A treatment treatment for cancer and inflammation comprising an effective amount of N-terminally truncated galectin-3 according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The treatment according to claim 11, wherein said N-terminally truncated galectin-3 wherein said N-terminally truncated galectin-3 has a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.

### Claim 13 (depends on 12)

The treatment according to claim 12, wherein said analogues and homologues include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.

### Claim 14 (depends on 11)

The treatment according to claim 11, wherein said N-terminally truncated galectin-3 is present in an amount sufficient to prevent metastasis.

### Claim 15 (depends on 1)

An anti-cancer treatment comprising an effective amount of a nucleic acid sequence encoding an N-terminally truncated galectin-3 according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 13)

The treatment according to claim 13, wherein said nucleic acid sequence encoding the N-terminally truncated galectin-3 is present in an amount sufficient to prevent metastasis.

### Claim 17 (depends on 11)

The treatment according to claim 11, wherein said treatment is formulated for slow release.

### Claim 18

A nucleic acid sequence encoding for an N-terminally truncated galectin-3.

### Claim 19 (depends on 18)

The nucleic acid sequence according to claim 18, wherein said N-terminally truncated galectin-3 wherein said N-terminally truncated galectin-3 has a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.

### Claim 20 (depends on 19)

The nucleic acid sequences according to claim 19, wherein said analogues and homologues include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.

### Claim 21

A method of treating a tumor in a patient by administering to a patient in need of treatment an effective amount of a nucleic acid sequence encoding an N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier.

### Claim 22 (depends on 21)

The method according to claim 21, wherein said administering step includes administering the N-terminally truncated galectin-3 in a method selected from the group consisting essentially of intramuscularly, orally, intravenously, and locally.

### Claim 23

An antibody that specifically binds to carbohydrate ligands of galectin-3.

### Claim 24 (depends on 23)

The antibody according to claim 23, wherein said antibody is used for treating cancer.
